{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-016804","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.863315+00:00","generated_at":"2026-06-05T23:21:18.068381+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PepGen gets FDA Fast Track for PGN-EDODM1 in DM1; Phase 1 data due 2024","bullets":["FDA granted Fast Track designation for PGN-EDODM1 targeting myotonic dystrophy type 1 (DM1).","No approved therapies target root cause of DM1; PGN-EDODM1 aims to be disease-modifying.","Ongoing FREEDOM-DM1 Phase 1 trial (NCT06204809); preliminary data expected in 2024.","PGN-EDODM1 previously received FDA Orphan Drug Designation in September 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-016804","json":"https://secwatch.observer/filing/0000950170-24-016804.json","markdown":"https://secwatch.observer/filing/0000950170-24-016804.md","text":"https://secwatch.observer/filing/0000950170-24-016804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024016804/0000950170-24-016804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024016804/pepg-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:21:18.068381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}